2181.HK · MABPHARM-B
Hong Kong · RS rating 55 · As of 2026-11-03
| Price | 0.42 HKD |
|---|---|
| 1-day change | -1.2% |
| RS rating (overall / 1M / 3M / 12M) | 55 / 28 / 66 / 41 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 21 / 20 / 8 |
| Industry group (rank) | Pharma & Biotech (27) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +41.0% |
| Market cap (USD) | $228.6M |